The current stock price of STSS is 2.65 USD. In the past month the price decreased by -27.2%. In the past year, price decreased by -99.57%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.55 | 16.05B | ||
| SOLV | SOLVENTUM CORP | 13.79 | 14.21B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.02 | 11.81B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.96 | 5.06B | ||
| HAE | HAEMONETICS CORP/MASS | 18.16 | 4.08B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.2 | 4.03B | ||
| ICUI | ICU MEDICAL INC | 18.54 | 3.64B | ||
| XRAY | DENTSPLY SIRONA INC | 7.37 | 2.32B | ||
| UFPT | UFP TECHNOLOGIES INC | 24.77 | 1.65B | ||
| NEOG | NEOGEN CORP | 23.27 | 1.52B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.19B | ||
| EMBC | EMBECTA CORP | 3.89 | 675.21M |
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. The company is headquartered in Melville, New York and currently employs 5 full-time employees. The company went IPO on 2022-04-14. The firm is engaged in offering patented smart-safety syringe products to the healthcare industry. The firm's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. The company Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. The company also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The company has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.
SHARPS TECHNOLOGY INC
105 Maxess Road, Ste. 124
Melville NEW YORK US
Employees: 5
Phone: 15162464000
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company, which engages in the development and manufacturing of innovative drug delivery systems. The company is headquartered in Melville, New York and currently employs 5 full-time employees. The company went IPO on 2022-04-14. The firm is engaged in offering patented smart-safety syringe products to the healthcare industry. The firm's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. The company Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. The company also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The company has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.
The current stock price of STSS is 2.65 USD. The price decreased by -7.34% in the last trading session.
STSS does not pay a dividend.
STSS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SHARPS TECHNOLOGY INC (STSS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
SHARPS TECHNOLOGY INC (STSS) has a market capitalization of 74.81M USD. This makes STSS a Micro Cap stock.
You can find the ownership structure of SHARPS TECHNOLOGY INC (STSS) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to STSS. STSS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months STSS reported a non-GAAP Earnings per Share(EPS) of -689.83. The EPS increased by 72.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.51% | ||
| ROE | -24.09% | ||
| Debt/Equity | 0.02 |
7 analysts have analysed STSS and the average price target is 22.44 USD. This implies a price increase of 746.79% is expected in the next year compared to the current price of 2.65.
For the next year, analysts expect an EPS growth of -633.33% and a revenue growth -95.06% for STSS